Scotia Capital Inc. Aerovate Therapeutics, Inc. Transaction History
Scotia Capital Inc.
- $17.9 Billion
- Q4 2024
A detailed history of Scotia Capital Inc. transactions in Aerovate Therapeutics, Inc. stock. As of the latest transaction made, Scotia Capital Inc. holds 37,210 shares of AVTE stock, worth $88,187. This represents 0.0% of its overall portfolio holdings.
Number of Shares
37,210Holding current value
$88,187% of portfolio
0.0%Shares
1 transactions
Others Institutions Holding AVTE
# of Institutions
83Shares Held
30.7MCall Options Held
186KPut Options Held
269K-
Ra Capital Management, L.P. Boston, MA9.19MShares$21.8 Million0.39% of portfolio
-
Sofinnova Investments, Inc. Menlo Park, CA3.76MShares$8.91 Million0.81% of portfolio
-
Tcg Crossover Management, LLC Palo Alto, CA2.24MShares$5.31 Million0.97% of portfolio
-
Atlas Venture Life Science Advisors, LLC1.8MShares$4.26 Million0.79% of portfolio
-
Braidwell LP Stamford, CT1.44MShares$3.41 Million0.21% of portfolio
About Aerovate Therapeutics, Inc.
- Ticker AVTE
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 24,448,100
- Market Cap $57.9M
- Description
- Aerovate Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of drugs that enhance the lives of patients with rare cardiopulmonary diseases in the United States. The company focuses on advancing AV-101, a dry powder inhaled formulation of imatinib for the treatment of pulmonary arterial hypertension, which ...